Malignant Melanoma: Diagnosis, Staging, and Treatment

Malignant melanoma is a fascinating yet troublesome disease, often eliciting significant fear despite an 80% overall cure rate. While accounting for only 4% of all malignant neoplasms, it is responsible for over 77% of skin cancer deaths. Our understanding of this aggressive skin cancer continues to improve, helping differentiate low-risk from high-risk patients. This guide will cover its diagnosis, staging, and treatment, providing a clear overview for students.

Malignant Melanoma: Understanding Diagnosis

The definitive diagnosis of melanoma relies on histologic analysis. However, clinicians often use ABCDE criteria to identify suspicious pigmented lesions:

• Asymmetry: The lesion grows irregularly, losing its round or oval shape.
• Border irregularity: Uneven, notched, or scalloped edges due to varying growth rates.
• Color changes: Varied shades of pigment (brown, black, tan, red, white, blue) indicating pigment deposition at different depths.
• Diameter: Lesion grows larger than 6 mm (1/4 inch).
• Evolving: Changes in size, shape, symptoms (itching, tenderness), surface (bleeding), or shades of color. The "ugly duckling sign" – a lesion that looks different from a patient's other moles – is also a key indicator.

Clinical Features and Differential Diagnosis

While an experienced clinician may suspect melanoma by sight, confirmation always comes from histology. It's crucial to differentiate melanoma from other lesions like seborrheic keratosis, pyogenic granuloma, and pigmented basal cell carcinoma. Growth, bleeding, or inflammation can complicate visual diagnosis, making microscopic examination essential.

Common Nevi and Precursors to Melanoma:

• Junctional Nevus: Small, flat, smooth, nonpalpable light to dark brown/black lesions at the epidermis-dermis interface, appearing after birth.
• Compound Nevus: Matures from a junctional nevus, with a central elevated portion in the dermis and a flat junctional periphery.
• Intradermal Nevus: Common adult mole, elevated due to nevus cell proliferation in the dermis.
• Blue Nevus: Deep melanin deposits reflect blue light, giving a blue appearance.
• Congenital Nevus: Present at birth with pigment, potentially transforming into melanoma (2-42% risk). Large congenital nevi (over 40 cm) carry the highest risk.
• Atypical (Dysplastic) Nevus: Clinically large (>6 mm), macular, irregular margin, variegated color, often with erythema. Histologically, these show melanocytic hyperplasia and atypia. Patients with these are at greater risk for melanoma transformation.
• Hutchinson Freckle (Lentigo Maligna): A flat, brown, macular lesion on sun-exposed areas, typically in middle-aged or older adults. It's an in situ melanoma, and if invasive, it's called lentigo maligna melanoma.

Biopsy Procedures for Melanoma Diagnosis

Initial workup of a pigmented lesion should ideally be an excisional biopsy with a 1–2 mm margin of normal-appearing skin. This allows for reliable diagnosis and assessment of the thickest depth of invasion. If functional or cosmetic concerns prevent complete removal, incisional or punch biopsy may be performed. Shave biopsies are generally not preferred but may be acceptable for broad, superficial lesions or suspected subungual melanomas. Importantly, biopsy does not decrease cure rates.

Pathologic Details Required from Biopsy:

• Breslow depth (in millimeters): The most powerful prognostic indicator for survival.
• Presence/absence of ulceration.
• Mitotic rate per mm² (especially for lesions ≤ 1 mm thick).
• Peripheral and deep margin status.
• Clark level (especially for lesions ≤ 1 mm in depth).
• Other details: microscopic satellitosis, regression, tumor-infiltrating lymphocytes, neurotropism, and histologic subtype.

Melanoma Staging System: AJCC TNM Explained

Melanoma staging applies primarily to cutaneous lesions. The current (2010), seventh edition of the American Joint Committee on Cancer (AJCC) staging system uses the TNM system (Tumor, Node, Metastasis), along with serum lactate dehydrogenase (LDH) levels, to predict prognosis and guide treatment.

Understanding T Classification: Primary Tumor Characteristics

The T classification is based on the Breslow depth, presence/absence of ulceration, and mitotic rate.

• T1: ≤ 1.0 mm thick (subdivided by ulceration and mitotic rate < 1/mm² or ≥ 1/mm²).
• T2: 1.01–2.0 mm thick (subdivided by ulceration).
• T3: 2.01–4.0 mm thick (subdivided by ulceration).
• T4: > 4.0 mm thick (subdivided by ulceration).

Increasing tumor thickness correlates with poorer prognosis. Ulceration also indicates a worse outcome. The mitotic rate is the second most important prognostic factor for localized melanoma, especially for T1 lesions.

Histologic Subtypes of Melanoma:

• Superficial Spreading Melanoma: 50–80% of cases, grows radially before vertical growth.
• Nodular Melanoma: 20–30% of cases, rapidly enters vertical growth phase.
• Lentigo Maligna Melanoma: Occurs on sun-exposed surfaces, grows horizontally.
• Acral Lentiginous Melanoma: Appears on palms, soles, subungual areas. Often mistaken for fungal infections, leading to delayed diagnosis and poorer prognosis.
• Desmoplastic Melanoma: Less common, usually non-pigmented, resembles a hypertrophic scar, may demonstrate perineural invasion.
• Amelanotic Melanoma: Variant lacking sufficient pigment to appear dark, making diagnosis challenging.

Understanding N Classification: Regional Lymph Node Involvement

Melanoma primarily metastasizes through lymphatic channels. Evaluation of regional lymph nodes is critical as clinical assessment is often inaccurate. Lymphoscintigraphy (lymphatic mapping) and Sentinel Lymph Node Biopsy (SLNB) have largely replaced elective lymph node dissection (ELND).

Sentinel Lymph Node Biopsy (SLNB):

• Recommended for melanomas > 1 mm thick, and for thin melanomas (≤ 1 mm) with high-risk features like ulceration or high mitotic rate.
• Identifies the first lymph node(s) draining the primary tumor site. If these nodes are negative, the basin is usually tumor-free (96% of cases).
• The likelihood of a positive SLNB increases with primary lesion thickness.
• N1: 1 involved lymph node (micrometastasis or macrometastasis).
• N2: 2–3 involved nodes (micrometastases, macrometastases, or in-transit/satellite metastasis without nodal involvement).
• N3: 4 or more positive nodes, matted nodes, or in-transit/satellite metastases with positive nodes.

The presence of in-transit metastases or any nodal involvement classifies the patient as Stage III.

Understanding M Classification: Distant Metastases and Systemic Evaluation

Evaluation for systemic disease involves a complete physical examination, liver function tests, and imaging studies based on the primary diagnosis stage.

• Stage I & II: Chest X-ray and liver function tests.
• Stage III & IV (regional or systemic metastases): Comprehensive staging workup including CT scans (chest, abdomen, pelvis, brain) and PET imaging.
• Serum lactate dehydrogenase (LDH): Included in AJCC staging, as elevated levels portend a worse prognosis in metastatic disease.

M Classification Designations:

• M1a: Distant skin, subcutaneous, or nodal metastases with normal serum LDH (best prognosis).
• M1b: Lung metastases with normal serum LDH.
• M1c: All other visceral metastases or any distant metastasis with elevated serum LDH (worst prognosis).

Any M designation places the patient in Stage IV. An electronic prediction tool (melanomaprognosis.org) can help predict survival rates.

Malignant Melanoma Treatment Options

Successful treatment of melanoma relies heavily on surgical intervention, with adjuvant therapies playing a crucial role for high-risk patients.

Surgical Management: Wide Local Excision

The goal of wide local excision (WLE) is to reduce local recurrence. The recommended excision margins depend on the Breslow depth of the primary tumor:

• In situ melanoma: 0.5 cm margin.
• Invasive melanoma ≤ 1.0 mm (Stage IA): 1.0 cm margin.
• Invasive melanoma 1.01–2.0 mm: 1–2 cm margin (considering functional/cosmetic concerns).
• Invasive melanoma > 2.0 mm: At least 2.0 cm margin.

Special Considerations for Surgical Sites:

• Head and Neck: Account for 15-30% of melanomas. Flaps are preferred for reconstruction for better cosmetic results. Frozen section analysis or Mohs micrographic surgery may be considered for tissue conservation.
• Extremities: Thin melanomas of fingertips may use volar advancement flaps. Thicker finger lesions ( > 1 mm) are treated with interphalangeal joint amputation or ray amputation. Subungual melanoma of the hand requires resection at the distal interphalangeal joint to preserve function; for toes, digital amputation at the metatarsophalangeal joint. Local flaps are preferred over skin grafts for better function and cosmesis.
• Trunk: More liberal margins (2–4 cm) are possible, often closed with wide undermining or local flaps, preserving deep fascia and muscle if not involved.

Surgical Management: Lymphadenectomy

• Palpable Lymphadenopathy: Confirmed by biopsy, followed by wide excision of the primary site and complete dissection of the involved lymph node basin.
• Positive Sentinel Lymph Node: Patients should be offered complete dissection of the involved lymph node basin, as 15-20% may have melanoma in non-sentinel nodes.

Adjuvant Treatment for High-Risk Melanoma

For patients with Stage IIB-III disease, adjuvant therapies are considered to improve outcomes.

• Interferon-alpha (IFN-α): Has shown improvement in relapse-free survival, though not consistently in overall survival. The NCCN recommends consideration for Stage IIB-III resected disease or enrollment in clinical trials.

Radiation Therapy for Melanoma

While not primary treatment, adjuvant radiation may be considered when adequate surgical margins are not possible, or for specific high-risk features:

• Multiple positive lymph nodes, extracapsular spread, nodal recurrence, in-transit metastases.
• Primary melanomas with neurotropism (desmoplastic type).
• Mucosal melanomas.

High-dose, hypofractionated radiotherapy has shown some success, particularly for locoregional control, but concerns exist regarding its impact on overall survival and potential for distant metastases.

Isolated Limb Perfusion and Systemic Therapies

For advanced or metastatic melanoma, other treatment modalities include:

• Isolated Limb Perfusion (ILP): Delivers high-dose chemotherapy to an extremity while isolating it from systemic circulation, effective for recurrent in-transit metastases or unresectable primary tumors of the limb.
• Chemotherapy (e.g., Dacarbazine): Used for advanced disease, but single-agent response rates are low (15-20%).
• Immunotherapy (Interleukin-2, IL-2): Approved for metastatic melanoma, induces durable complete responses in a small subset of highly selected patients but carries high toxicity.
• Biochemotherapy (chemotherapy + IFN-α + IL-2): Improved response rates but not consistently overall survival, with substantial toxicity.
• Targeted Therapies: For specific genetic mutations (e.g., BRAF inhibitors like Vemurafenib for BRAF V600E mutation).
• Ipilimumab: An immune checkpoint inhibitor (anti-CTLA-4 antibody) approved for advanced melanoma, has shown improved overall survival.
• Cancer Vaccines: Under investigation to stimulate tumor-specific immune responses.

Management of Recurrence

Most recurrences (60-70%) appear within 18-24 months post-surgery, initially local or regional, then distant. Regular follow-up with physical examinations and imaging is crucial. The NCCN provides guidelines for post-treatment surveillance based on disease stage.

Frequently Asked Questions by Students about Melanoma

How is melanoma diagnosed initially, and what are the key clinical signs I should know?

Melanoma is initially diagnosed through a clinical evaluation using the ABCDE criteria (Asymmetry, Border irregularity, Color changes, Diameter > 6mm, Evolving). The definitive diagnosis, however, is always confirmed by a histologic analysis of a biopsy sample. Early detection is key, so pay attention to any changing moles or lesions that fit these criteria.

What are the main factors determining melanoma's stage, and why is staging important?

Melanoma staging uses the AJCC TNM system, based on the primary tumor's characteristics (T-classification: Breslow depth, ulceration, mitotic rate), regional lymph node involvement (N-classification: number of positive nodes, micrometastasis/macrometastasis), and presence of distant metastases (M-classification). Staging is crucial because it predicts prognosis, helps determine the aggressiveness of the disease, and guides the appropriate treatment strategy.

Can you summarize the primary treatment approaches for localized versus advanced melanoma?

For localized melanoma (Stage I and II), the primary treatment is surgical wide local excision of the tumor with clear margins. Depending on the depth and risk features, sentinel lymph node biopsy may be performed. For high-risk localized disease (Stage IIB-III), adjuvant treatment with interferon-alpha or enrollment in clinical trials might be considered. For advanced or metastatic melanoma (Stage IV), treatment becomes more complex, involving systemic therapies such as chemotherapy, immunotherapy (like IL-2 or ipilimumab), and targeted therapies for specific genetic mutations. Radiation therapy may be used in specific palliative or locoregional control scenarios.